These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9302183)

  • 21. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
    BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 3 investigational assays for the free form of prostate specific antigen.
    Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
    J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
    Ornstein DK; Smith DS; Humphrey PA; Catalona WJ
    J Urol; 1998 Apr; 159(4):1234-7. PubMed ID: 9507843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
    Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
    Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
    Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
    Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Concentrations of free form and complex form of prostate-specific antigen in serum of alpha 2 macroglobulin deficient patients with prostatic carcinoma].
    Kanoh Y; Jimbo S; Shibuya M; Matsuyama N; Mashiko T; Tanaka T; Egawa S; Ohtani H
    Rinsho Byori; 1998 Sep; 46(9):923-9. PubMed ID: 9800478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort.
    Capitanio U; Perrotte P; Zini L; Suardi N; Antebi E; Cloutier V; Jeldres C; Shariat SF; Duclos A; Arjane P; Saad F; Montorsi F; Karakiewicz PI
    Urology; 2009 Jun; 73(6):1323-7. PubMed ID: 19376563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biologic lower detection limit of six ultrasensitive PSA assays.
    Junker R; Brandt B; Semjonow A; Erren M; Zechel C; Assmann G
    Anticancer Res; 1999; 19(4A):2625-8. PubMed ID: 10470206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification of human prostatic-specific antigen (hPSA) from seminal plasma by immunoaffinity chromatography using a monoclonal antibody anti total PSA.
    Pérez L; Zulueta O; Melchor A; Hernández L; López R; Cazanave J; Béquer D
    Hybridoma (Larchmt); 2011 Jun; 30(3):247-51. PubMed ID: 21707359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin.
    Chen Z; Komatsu K; Prestigiacomo A; Stamey TA
    J Urol; 1996 Oct; 156(4):1357-63. PubMed ID: 8808871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization and measurement of prostate-specific antigen using monoclonal antibodies.
    Bélanger A; Rong PM; Liu S; Lavoie L; Labrie F
    Clin Invest Med; 1993 Dec; 16(6):409-14. PubMed ID: 7516829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.